General Announcement::Glenmark becomes the first company to launch fixed dose combination for Type 2 Diabetes in India

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
26-Oct-2021 13:20:35
Status
New
Announcement Sub Title
Glenmark becomes the first company to launch fixed dose combination for Type 2 Diabetes in India
Announcement Reference
SG211026OTHRZXSI
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
26/10/2021 17:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark becomes the first company to launch Remogliflozin, Vildagliptin and Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

Attachments

SGX_PR_26102021.pdf
Total size =2294K